TipRanks
55% OFF
PC:TRELL

Trellis Bioscience

A clinical-stage biotechnology company developing native human monoclonal antibodies to treat intractable infectious diseases. Focused on advancing calpurbatug (TRL1068), an investigational monoclonal antibody being evaluated for chronic prosthetic joint infections (PJI).

Leadership & Board

Latest Estimated Valuation

Estimated Valuation
―
Total Amount Raised
$9M
Total Funding Rounds
1
Latest Funding Amount
$9M
Latest Funding Round
Series C
Post-Money Valuation
―

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Jul 16, 2026Series C$9.00M―

Similar Companies

A snapshot of private companies similar to Trellis Bioscience, helping you discover and navigate related company profiles.

Related News and Analysis